Skip to main content
. 2014 Oct 16;2014(3):257–290. doi: 10.5339/gcsp.2014.42

Figure 8.

Figure 8.

The initial results of first unpublished data of the role of intravenous sildenafil on pulmonary vascular resistance (PVR) in 12 patients with either pulmonary arterial hypertension (PAH)(left) or patients with venous pulmonary hypertension (heart failure patients (PVH) (right); using three doses of sildenafil to achieve a plasma level equivalent to taking oral tablets of 25, 50 or 100 mg of sildenafil.